Drugs / JY232
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07336823 | Jan 2026 → Dec 2028 expected | plasma cell myeloma | Shenzhen Genocury Biotech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JY232 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07336823 ↗ |
| Route | Intravenous | “receive a single intravenous infusion of JY232” NCT07336823 ↗ |